Sam Chun Dang Pharm Balance Sheet Health
Financial Health criteria checks 5/6
Sam Chun Dang Pharm has a total shareholder equity of ₩356.4B and total debt of ₩55.5B, which brings its debt-to-equity ratio to 15.6%. Its total assets and total liabilities are ₩493.3B and ₩136.9B respectively. Sam Chun Dang Pharm's EBIT is ₩5.2B making its interest coverage ratio -1.8. It has cash and short-term investments of ₩161.0B.
Key information
15.6%
Debt to equity ratio
₩55.54b
Debt
| Interest coverage ratio | -1.8x |
| Cash | ₩161.03b |
| Equity | ₩356.38b |
| Total liabilities | ₩136.91b |
| Total assets | ₩493.29b |
Recent financial health updates
Here's Why Sam Chun Dang Pharm (KOSDAQ:000250) Has A Meaningful Debt Burden
Dec 22
Sam Chun Dang Pharm (KOSDAQ:000250) Takes On Some Risk With Its Use Of Debt
Sep 08Is Sam Chun Dang Pharm (KOSDAQ:000250) A Risky Investment?
Jun 09Sam Chun Dang Pharm (KOSDAQ:000250) Seems To Use Debt Quite Sensibly
Feb 26Here's Why Sam Chun Dang Pharm (KOSDAQ:000250) Can Manage Its Debt Responsibly
Dec 01
Recent updates
Here's Why Sam Chun Dang Pharm (KOSDAQ:000250) Has A Meaningful Debt Burden
Dec 22Risks Still Elevated At These Prices As Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) Shares Dive 26%
Nov 30Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) Investors Are Less Pessimistic Than Expected
Oct 05Sam Chun Dang Pharm (KOSDAQ:000250) Takes On Some Risk With Its Use Of Debt
Sep 08Subdued Growth No Barrier To Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) With Shares Advancing 44%
Jun 19Is Sam Chun Dang Pharm (KOSDAQ:000250) A Risky Investment?
Jun 09Optimistic Investors Push Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) Shares Up 28% But Growth Is Lacking
Mar 21Sam Chun Dang Pharm (KOSDAQ:000250) Seems To Use Debt Quite Sensibly
Feb 26Investors Who Bought Sam Chun Dang Pharm (KOSDAQ:000250) Shares Five Years Ago Are Now Up 644%
Feb 09Could The Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) Ownership Structure Tell Us Something Useful?
Jan 05Here's Why Sam Chun Dang Pharm (KOSDAQ:000250) Can Manage Its Debt Responsibly
Dec 01Financial Position Analysis
Short Term Liabilities: A000250's short term assets (₩239.0B) exceed its short term liabilities (₩58.3B).
Long Term Liabilities: A000250's short term assets (₩239.0B) exceed its long term liabilities (₩78.6B).
Debt to Equity History and Analysis
Debt Level: A000250 has more cash than its total debt.
Reducing Debt: A000250's debt to equity ratio has increased from 9.6% to 15.6% over the past 5 years.
Debt Coverage: A000250's debt is well covered by operating cash flow (69.1%).
Interest Coverage: A000250 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 14:43 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sam Chun Dang Pharm. Co., Ltd is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyung Soo Kim | Cape Investment & Securities Co., Ltd. |
| Al Eum Lee | iM Securities |
| Hong-Sik Jeong | LS Securities Co., Ltd. |